Author:
Beyer Susanne,Müller Lena,Mitter Sophie,Keilmann Lucia,Meister Sarah,Buschmann Christina,Kraus Fabian,Topalov Nicole E.,Czogalla Bastian,Trillsch Fabian,Burges Alexander,Mahner Sven,Schmoeckel Elisa,Löb Sanja,Corradini Stefanie,Kessler Mirjana,Jeschke Udo,Kolben Thomas
Abstract
Abstract
Purpose
Endometrial cancer is the most common gynecological malignancy. The helicase RIG-I, a part of the innate immune system, and EFTUD2, a splicing factor which can upregulate RIG-I expression, are shown to influence tumor growth and disease progression in several malignancies. For endometrial cancer, an immunogenic cancer, data about RIG-I and EFTUD2 are still missing. The aim of this study was to examine the expression of RIG-I and EFTUD2 in endometrial cancer.
Methods
225 specimen of endometrial cancer were immunohistochemically stained for RIG-I and EFTUD2. The results were correlated to clinicopathological data, overall survival (OS) and progression-free survival (PFS).
Results
High RIG-I expression correlated with advanced tumor stages (FIGO: p = 0.027; pT: p = 0.010) and worse survival rates (OS: p = 0.009; PFS: p = 0.022). High EFTUD2 expression correlated to worse survival rates (OS: p = 0.026; PFS: p < 0.001) and was determined to be an independent marker for progression-free survival.
Conclusion
Our data suggest that the expression of RIG-I and EFTUD2 correlates with survival data, which makes both a possible therapeutic target in the future.
Funder
Universitätsklinik München
Publisher
Springer Science and Business Media LLC
Subject
Cancer Research,Oncology,General Medicine
Reference57 articles.
1. AGO-S3-Leitlinie: Diagnostik, Version 1.0 – April 2018. Available from: https://www.awmf.org/uploads/tx_szleitlinien/032-034OLl_S3_Endometriumkarzinom-Diagnostik-Therpie-Nachsorge_2018-04.pdf. Accessed 15 Jul 2022
2. Asghar U, Meyer T (2012) Are there opportunities for chemotherapy in the treatment of hepatocellular cancer? J Hepatol 56(3):686–695
3. Boelens MC, Wu TJ, Nabet BY, Xu B, Qiu Y, Yoon T, Azzam DJ, Twyman-Saint Victor C, Wiemann BZ, Ishwaran H, Ter Brugge PJ, Jonkers J, Slingerland J, Minn AJ (2014) Exosome transfer from stromal to breast cancer cells regulates therapy resistance pathways. Cell 159(3):499–513
4. Bokhman JV (1983) Two pathogenetic types of endometrial carcinoma. Gynecol Oncol 15(1):10–17
5. Braun MM, Overbeek-Wager EA, Grumbo RJ (2016) Diagnosis and management of endometrial cancer. Am Fam Physician 93(6):468–474
Cited by
2 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献